The Simultaneous Onset of Pancreatitis and Colitis As Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.
Internal medicine(2022)
摘要
Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.
更多查看译文
关键词
immune checkpoint inhibitor,immune-related adverse event,pancreatitis,colitis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要